Literature DB >> 10468672

Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases.

M Trauner1, I W Graziadei.   

Abstract

Ursodeoxycholic acid (ursodiol) is a non-toxic, hydrophilic bile acid used to treat predominantly cholestatic liver disorders. Better understanding of the cellular and molecular mechanisms of action of ursodeoxycholic acid has helped to elucidate its cytoprotective, anti-apoptotic, immunomodulatory and choleretic effects. Ursodeoxycholic acid prolongs survival in primary biliary cirrhosis and it improves biochemical parameters of cholestasis in various other cholestatic disorders including primary sclerosing cholangitis, intrahepatic cholestasis of pregnancy, cystic fibrosis and total parenteral nutrition-induced cholestasis. However, a positive effect on survival remains to be established in these diseases. Ursodeoxycholic acid is of unproven efficacy in non-cholestatic disorders such as acute rejection after liver transplantation, non-alcoholic steatohepatitis, alcoholic liver disease and chronic viral hepatitis. This review outlines the present knowledge of the modes of action of ursodeoxycholic acid, and presents data from clinical trials on its use in chronic liver diseases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10468672     DOI: 10.1046/j.1365-2036.1999.00596.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  29 in total

1.  Bile acid-induced Mallory body formation in drug-primed mouse liver.

Authors:  Peter Fickert; Michael Trauner; Andrea Fuchsbichler; Conny Stumptner; Kurt Zatloukal; Helmut Denk
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

2.  Toxic hepatitis after sequential administration of flutamide and cyproterone acetate.

Authors:  Spilios Manolakopoulos; Sotirios Bethanis; Anastasios Armonis; Michalis Economou; Alec Avgerinos; Dimitrios Tzourmakliotis
Journal:  Dig Dis Sci       Date:  2004-03       Impact factor: 3.199

Review 3.  Primary sclerosing cholangitis: updates in diagnosis and therapy.

Authors:  Piero Portincasa; Michele Vacca; Antonio Moschetta; Michele Petruzzelli; Giuseppe Palasciano; Karel J van Erpecum; Gerard P van Berge-Henegouwen
Journal:  World J Gastroenterol       Date:  2005-01-07       Impact factor: 5.742

4.  Effects of ursodeoxycholic acid and/or low-calorie diet on steatohepatitis in rats with obesity and hyperlipidemia.

Authors:  Jian-Gao Fan; Lan Zhong; Li-Yan Tia; Zheng-Jie Xu; Min-Sheng Li; Guo-Liang Wang
Journal:  World J Gastroenterol       Date:  2005-04-21       Impact factor: 5.742

5.  Structural requirements of bile acid transporters: C-3 and C-7 modifications of steroidal hydroxyl groups.

Authors:  Vidula Kolhatkar; James E Polli
Journal:  Eur J Pharm Sci       Date:  2012-03-03       Impact factor: 4.384

Review 6.  Use of ursodeoxycholic acid in patients with liver disease.

Authors:  Paul Angulo
Journal:  Curr Gastroenterol Rep       Date:  2002-02

Review 7.  Molecular mechanisms of cholestasis.

Authors:  Gernot Zollner; Michael Trauner
Journal:  Wien Med Wochenschr       Date:  2006-07

8.  Effect of ursodeoxycholic acid on liver markers: A systematic review and meta-analysis of randomized placebo-controlled clinical trials.

Authors:  Mario Simental-Mendía; Adriana Sánchez-García; Luis E Simental-Mendía
Journal:  Br J Clin Pharmacol       Date:  2020-04-27       Impact factor: 4.335

Review 9.  Ursodeoxycholic acid treatment of vanishing bile duct syndromes.

Authors:  Thomas Pusl; Ulrich Beuers
Journal:  World J Gastroenterol       Date:  2006-06-14       Impact factor: 5.742

Review 10.  Primary biliary cirrhosis.

Authors:  Simon Hohenester; Ronald P J Oude-Elferink; Ulrich Beuers
Journal:  Semin Immunopathol       Date:  2009-07-15       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.